444 related articles for article (PubMed ID: 10225538)
1. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
Geis GS
J Rheumatol Suppl; 1999 Apr; 56():31-6. PubMed ID: 10225538
[TBL] [Abstract][Full Text] [Related]
2. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
Geis GS
Scand J Rheumatol Suppl; 1999; 109():31-7. PubMed ID: 10422544
[TBL] [Abstract][Full Text] [Related]
3. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects.
Simon LS; Lanza FL; Lipsky PE; Hubbard RC; Talwalker S; Schwartz BD; Isakson PC; Geis GS
Arthritis Rheum; 1998 Sep; 41(9):1591-602. PubMed ID: 9751091
[TBL] [Abstract][Full Text] [Related]
4. Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results.
Tindall E
J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S13-7. PubMed ID: 10643176
[TBL] [Abstract][Full Text] [Related]
5. Celecoxib, a COX-2--specific inhibitor: the clinical data.
Fort J
Am J Orthop (Belle Mead NJ); 1999 Mar; 28(3 Suppl):13-8. PubMed ID: 10193998
[TBL] [Abstract][Full Text] [Related]
6. Antiinflammatory and analgesic efficacy of COX-2 specific inhibition: from investigational trials to clinical experience.
Bensen WG
J Rheumatol Suppl; 2000 Oct; 60():17-24. PubMed ID: 11032098
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacology of selective COX-2 inhibitors.
Capone ML; Tacconelli S; Sciulli MG; Patrignani P
Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):49-58. PubMed ID: 14552704
[TBL] [Abstract][Full Text] [Related]
8. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
Bensen WG; Zhao SZ; Burke TA; Zabinski RA; Makuch RW; Maurath CJ; Agrawal NM; Geis GS
J Rheumatol; 2000 Aug; 27(8):1876-83. PubMed ID: 10955327
[TBL] [Abstract][Full Text] [Related]
9. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
Jacoby RF; Seibert K; Cole CE; Kelloff G; Lubet RA
Cancer Res; 2000 Sep; 60(18):5040-4. PubMed ID: 11016626
[TBL] [Abstract][Full Text] [Related]
10. Pain management in osteoarthritis: the role of COX-2 inhibitors.
Lane NE
J Rheumatol Suppl; 1997 Jul; 49():20-4. PubMed ID: 9249647
[TBL] [Abstract][Full Text] [Related]
11. Outcome of specific COX-2 inhibition in rheumatoid arthritis.
Lipsky PE; Isakson PC
J Rheumatol Suppl; 1997 Jul; 49():9-14. PubMed ID: 9249645
[TBL] [Abstract][Full Text] [Related]
12. Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis.
Goldenberg MM
Clin Ther; 1999 Sep; 21(9):1497-513; discussion 1427-8. PubMed ID: 10509845
[TBL] [Abstract][Full Text] [Related]
13. Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice.
Wolfe F; Michaud K; Burke TA; Zhao SZ
J Rheumatol; 2004 Feb; 31(2):355-8. PubMed ID: 14760808
[TBL] [Abstract][Full Text] [Related]
14. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
Hochberg MC
Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
[TBL] [Abstract][Full Text] [Related]
15. Defining COX-2 inhibitors.
Lipsky PE
J Rheumatol Suppl; 2000 Oct; 60():13-6. PubMed ID: 11032097
[TBL] [Abstract][Full Text] [Related]
16. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.
Simon LS; Weaver AL; Graham DY; Kivitz AJ; Lipsky PE; Hubbard RC; Isakson PC; Verburg KM; Yu SS; Zhao WW; Geis GS
JAMA; 1999 Nov; 282(20):1921-8. PubMed ID: 10580457
[TBL] [Abstract][Full Text] [Related]
17. [Coxibs: cyclooxygenase-2 inhibitors].
Turnheim K
Wien Klin Wochenschr; 2001 Aug; 113(15-16):558-65. PubMed ID: 11571832
[TBL] [Abstract][Full Text] [Related]
18. Scientific rationale for specific inhibition of COX-2.
Bolten WW
J Rheumatol Suppl; 1998 May; 51():2-7. PubMed ID: 9596548
[TBL] [Abstract][Full Text] [Related]
19. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.
Reddy BS; Hirose Y; Lubet R; Steele V; Kelloff G; Paulson S; Seibert K; Rao CV
Cancer Res; 2000 Jan; 60(2):293-7. PubMed ID: 10667579
[TBL] [Abstract][Full Text] [Related]
20. [Preferential COX-2 inhibition: its clinical relevance for gastrointestinal non-steroidal anti-inflammatory rheumatic drug toxicity].
Dammann HG
Z Gastroenterol; 1999 Jan; 37(1):45-58. PubMed ID: 10091284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
